Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics

Modern Pathology

Volumn 27, Issue 3, 2014, Pages 390-395

  Doyle, Leona A ^a   Vivero, Marina ^a   Fletcher, Christopher D M ^a   Mertens, Fredrik ^b   Hornick, Jason L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Gene fusion; Immunohistochemistry; Sarcoma; Soft tissue tumors; Whole exome sequencing

Indexed keywords

STAT6 PROTEIN; TUMOR MARKER;

ARTICLE; CHROMOSOME BAND; CONTROLLED STUDY; DERMATOFIBROMA; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIPOSARCOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SOLITARY FIBROUS TUMOR; TISSUE SECTION; TUMOR CLASSIFICATION; TUMOR LOCALIZATION;

CELL NUCLEUS; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; SOFT TISSUE NEOPLASMS; SOLITARY FIBROUS TUMORS; STAT6 TRANSCRIPTION FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 84896711912     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.164     Document Type: Article

References (30)

1. Klemperer P, Rabin CB. Primary neoplasms of the pleura: a report of five cases. Arch Pathol 1931;11: 385-412.
2. Hanau CA, Miettinen M. Solitary fibrous tumor: histological and immunohistochemical spectrum of benign and malignant variants presenting at different sites. Hum Pathol 1995;26: 440-449.
3. Brunnemann RB, Ro JY, Ordonez NG, et al. Extrapleural solitary fibrous tumor: a clinicopathologic study of 24 cases. Mod Pathol 1999;12: 1034-1042.
4. de Saint Aubain Somerhausen N, Rubin BP, Fletcher CD. Myxoid solitary fibrous tumor: a study of seven cases with emphasis on differential diagnosis. Mod Pathol 1999;12: 463-471.
5. Hasegawa T, Matsuno Y, Shimoda T, et al. Extrathoracic solitary fibrous tumors: their histological variability and potentially aggressive behavior. Hum Pathol 1999;30: 1464-1473.
6. Ng TL, Gown AM, Barry TS, et al. Nuclear beta-catenin in mesenchymal tumors. Mod Pathol 2005;18: 68-74.
7. Rao N, Colby TV, Falconieri G, et al. Intrapulmonary solitary fibrous tumors: clinicopathologic and immunohistochemical study of 24 cases. Am J Surg Pathol 2013;37: 155-166.
8. Renshaw AA. O13 (CD99) in spindle cell tumors: reactivity with hemangiopericytoma, solitary fibrous tumor, synovial sarcoma, and meningioma but rarely with sarcomatoid mesothelioma. Appl Immunohistochem 1995;3: 250-256.
9. Suster S, Fisher C, Moran CA. Expression of bcl-2 oncoprotein in benign and malignant spindle cell tumors of soft tissue, skin, serosal surfaces, and gastrointestinal tract. Am J Surg Pathol 1998;22: 863-872.
10. Chilosi M, Facchettti F, Dei Tos AP, et al. Bcl-2 expression in pleural and extrapleural solitary fibrous tumours. J Pathol 1997;181: 362-367.
11. Robinson DR, Wu YM, Kalyana-Sundaram S, et al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet 2013;45: 180-185.
12. Chmielecki J, Crago AM, Rosenberg M, et al. Wholeexome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet 2013;45: 131-132.
13. Mohajeri A, Tayebwa J, Collin A, et al. Comprehensive genetic analysis identifies a pathognomonic NAB2/ STAT6 fusion gene, non-random secondary genomic imbalances, and a characteristic gene expression profile in solitary fibrous tumor. Genes Chromosomes Cancer 2013;52: 873-886.
14. Calonje E, Fletcher CDM. Hemangiopericytoma. In: Fletcher CD (ed). Diagnostic Histopathology of Tumors, 3rd edn. Churchill Livingstone/Elsevier: Edinburgh, UK; 2007, pp 72-74.
15. Schweizer L, Koelsche C, Sahm F, et al. Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol 2013;125: 651-658.
16. Fletcher CDM, Bridge JA, Lee J-C. Extrapleural solitary fibrous tumour; In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F (eds). WHO Classification of Tumours of Soft Tissue and Bone. IARC: Lyon, France, 2013, pp 80-82.
17. Demicco EG, Park MS, Araujo DM, et al. Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model. Mod Pathol 2012;25: 1298-1306.
18. Bromberg J, Darnell JE Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000;19: 2468-2473.
19. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002;8: 945-954.
20. Kumbrink J, Kirsch KH, Johnson JP. EGR1, EGR2, and EGR3 activate the expression of their coregulator NAB2 establishing a negative feedback loop in cells of neuroectodermal and epithelial origin. J Cell Biochem 2010;111: 207-217.
21. Binh MB, Sastre-Garau X, Guillou L, et al. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol 2005;29: 1340-1347.
22. Dei Tos AP, Doglioni C, Piccinin S, et al. Coordinated expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumours. J Pathol 2000;190: 531-536.
23. Sandberg AA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: liposarcoma. Cancer Genet Cytogenet 2004;155: 1-24.
24. Espinosa I, Lee CH, Kim MK, et al. A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol 2008;32: 210-218.
25. Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am J Surg Pathol 2009;33: 1401-1408.
26. West RB, Corless CL, Chen X, et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol 2004;165: 107-113.
27. Baird K, Davis S, Antonescu CR, et al. Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res 2005;65: 9226-9235.
28. Nielsen TO, West RB, Linn SC, et al. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 2002;359: 1301-1307.
29. Moller E, Hornick JL, Magnusson L, et al. FUSCREB3L2/ L1-positive sarcomas show a specific gene expression profile with upregulation of CD24 and FOXL1. Clin Cancer Res 2011;17: 2646-2656.
30. Doyle LA, Moller E, Dal Cin P, et al. MUC4 is a highly sensitive and specific marker for low-grade fibromyxoid sarcoma. Am J Surg Pathol 2011;35: 733-741.